Singapore’s S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara
This article was originally published in The Pink Sheet Daily
The multi-kinase inhibitor might have stalled after S*BIO focused on funding its first two candidates in the clinic, CEO says. The company is still involved in preclinical development.
You may also be interested in...
PERTH, Australia - Singapore-based S*BIO inked a development collaboration and option and license agreement with Onyx Pharmaceuticals for S*BIO's two JAK2 inhibitors SB1518 and SB1578, S*BIO announced Jan. 6
Founded in 2000 as a joint venture between Chiron and the Economic Development Board of Singapore, S*BIO was one of the first biotech companies in Singapore. The company's pipeline consists of novel targeted small molecule drugs for the treatment of cancer with leading programs around histonedeacetylases and kinases. S*BIO announced Oct. 20 completion of a $26 million Series-B financing led by Bio*One Capital and Aravis Venture, which will allow the company to more forward into Phase II clinical development of its two lead oncology compounds. S*BIO CEO Jan-Anders Karlsson recently sat down with PharmAsia News' Australia bureau to discuss its pipeline and operations out of Singapore.
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.